Chimerix (NASDAQ:CMRX) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Chimerix (NASDAQ:CMRX) from a sell rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

Other research analysts also recently issued research reports about the stock. Cowen reaffirmed a hold rating and set a $3.00 price objective on shares of Chimerix in a research note on Thursday, May 9th. Zacks Investment Research downgraded shares of Chimerix from a buy rating to a hold rating in a research note on Wednesday, July 10th. Finally, HC Wainwright upped their price objective on shares of Chimerix from $5.00 to $7.00 and gave the company a buy rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Chimerix presently has an average rating of Hold and an average target price of $4.00.

NASDAQ:CMRX traded down $0.16 on Thursday, reaching $3.30. The stock had a trading volume of 315,421 shares, compared to its average volume of 415,408. The stock has a market cap of $176.71 million, a P/E ratio of -2.31 and a beta of 1.24. The stock’s fifty day simple moving average is $3.67. Chimerix has a 12-month low of $1.74 and a 12-month high of $4.51.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.35). Chimerix had a negative net margin of 757.77% and a negative return on equity of 36.85%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts expect that Chimerix will post -1.02 EPS for the current year.

In other Chimerix news, Director Fred A. Middleton bought 30,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average price of $2.92 per share, with a total value of $87,600.00. Following the transaction, the director now owns 97,523 shares in the company, valued at $284,767.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Martha J. Demski bought 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were acquired at an average cost of $3.60 per share, with a total value of $64,800.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 78,000 shares of company stock valued at $256,800. Corporate insiders own 9.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of CMRX. Citigroup Inc. increased its position in Chimerix by 81.2% during the 4th quarter. Citigroup Inc. now owns 19,570 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 8,771 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Chimerix by 2.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock worth $6,715,000 after purchasing an additional 56,347 shares in the last quarter. Geode Capital Management LLC increased its position in Chimerix by 21.6% during the 4th quarter. Geode Capital Management LLC now owns 645,273 shares of the biopharmaceutical company’s stock worth $1,658,000 after purchasing an additional 114,702 shares in the last quarter. Two Sigma Investments LP increased its position in Chimerix by 52.9% during the 4th quarter. Two Sigma Investments LP now owns 308,732 shares of the biopharmaceutical company’s stock worth $793,000 after purchasing an additional 106,750 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Chimerix by 18.1% during the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 20,700 shares in the last quarter. 69.52% of the stock is owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: Put Option Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.